Abhi Dey is Senior Associate at RM Global (US Office). He is an accomplished scientific and business development professional. He received his PhD in Molecular Biophysics from Indian Institute of Science in Bangalore, India. He has R&D leadership background with 10+ years of combined experience in pre-clinical drug development (small molecules, siRNA, biologics, and cell therapies)
As a scientist, he co-led research grants/awards worth more than $30M and published 15 scientific articles in drug delivery, assay development, biomarker discovery and drug discovery with 2 patents (pending). He established an industry alliance for Emory University with Moleculin Biotech and led preclinical development of a STAT3 inhibitor resulting in a Phase 1 clinical trial for precision medicine in medulloblastomas. He led strategy development as a Scientific Director, in the pre-clinical phase for MicroCures Inc (a NY-based siRNA therapeutics startup) in Immuno-Oncology, Oncology, Dermatology and Ophthalmology (served a co-PI in SBIR/STTR grants worth more than $2M and filed a patent as an inventor in cell therapy of solid tumors).
Prior to joining RM Global, he was the Manager of Business Development at the venture capital arm of a biotech start-up, Greenfire Bio. He was involved in multiple roles related to external innovation, competitive intelligence, corporate and business development focused on developing innovative strategies that drive business growth, transform operating models and optimize productivity. He was co-leading the search & evaluation of novel assets across different therapeutic areas as well pursuing investment opportunities for assets in the pipeline. He also served as an analyst with The Solution Lab, a NY-based consulting firm, on multiple client-facing projects related to oncology drug development landscape.
Broker-dealer services are provided through Beech Hill Securities ( http://www.beechhillsecurities.com/ ), Inc., a FINRA/SIPC member.